Article
Genetics & Heredity
Yahui Li, Yingjie Feng, Xiaohui Si, Chenjin Zhao, Fanping Wang, Xinqing Niu
Summary: ATO shows anti-tumor effects in AML treatment, especially regulating proliferation, apoptosis, and cell cycle in KG-1a cells, offering potential to enhance its efficacy.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, General & Internal
Yu-Cling Pan, Min Niu, Shu-min Liu, Yu-Xia Bao, Kai Yang, Xiao-Bo Ma, Liang He, Yi-Xun Li, Jie-Xian Cao, Xi Zhang, Yan Du
Summary: Accumulating evidence suggests that MT2A plays a crucial role in the occurrence and development of AML. MT2A over-expression inhibits cell reproductive capacity, increases apoptosis rate, reduces Bcl2 expression, and enhances Bax expression, leading to G2/M phase arrest. Conversely, interference with MT2A expression significantly increases cell proliferative potential, indicating a potential role of MT2A in AML cell growth and function via the NF-κB signaling pathway.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Oncology
Yu Zheng, Yuan-Fei Mao, Hui-Jin Zhao, Li Chen, Li-Ning Wang, Yun-Xiang Zhang, Jiong Hu, Jun-Min Li, Xiao-Yang Li, Hong-Ming Zhu
Summary: This study investigated the arsenic metabolism in APL patients who completed ATO treatment and found a decreased arsenic methylation capacity after treatment. The increased proportion of iAs(III) in urine was associated with chronic liver toxicity, highlighting the importance of monitoring urine PMI and considering SNPs of the AS3MT gene in determining ATO dosage.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jang Mi Han, Hong Lae Kim, Hye Jin Jung
Summary: Ampelopsin (dihydromyricetin), a plant-derived flavonoid, significantly inhibits the proliferation of two leukemia cell lines while not affecting the viability of normal cells. Its anticancer effects include cell cycle regulation, induction of apoptosis, and downregulation of signaling pathways. Ampelopsin shows promise as an attractive chemotherapeutic agent against leukemia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Medicinal
Judith A. Carrall, Wilford Lie, Jacob M. Lambert, Hugh H. Harris, Barry Lai, Carolyn T. Dillon
Summary: This research aims to design and develop tumor-homing peptide complexes of arsenic to strategically target specific cancers, with the goal of achieving dose reduction and decreased side effects. Studies show that the most stable complex exhibits 1000 times greater toxicity towards leukemia cells than human blood cells, indicating potential for in vivo studies.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Jian Lv, Mengliang Wu, Chunrong Pang, Rui Duan, Hong Zhang, Shuo Tian, Haixia Yang, Xin Hai
Summary: Torsemide increased the plasma concentrations of arsenic metabolites in APL patients treated with ATO by inhibiting the transporter MRP4 in a dose-dependent manner. This effect was also observed in rats treated with both ATO and torsemide. Torsemide reduced the excretion of arsenic in urine and increased its concentration in the kidneys of rats.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Qun Lou, Meichen Zhang, Yanmei Yang, Yanhui Gao
Summary: Long term low dose exposure to arsenic can lead to cell proliferation and malignant transformation. In this study, it was found that low dose exposure to arsenic trioxide increased glucose uptake and promoted cell viability and DNA synthesis. The activation of AKT induced by arsenic trioxide upregulated the expression of GLUT1 on the plasma membrane, enhancing glucose uptake and cell proliferation.
Review
Chemistry, Medicinal
Guangzhi Liu, Yurong Song, Chenxi Li, Rui Liu, Youwen Chen, Liuchunyang Yu, Qingcai Huang, Dongjie Zhu, Cheng Lu, Xue Yu, Cheng Xiao, Yuanyan Liu
Summary: Arsenic and its compounds have been utilized for nearly 4000 years, showing important therapeutic roles in treating diseases like acute promyelocytic leukemia. However, long-term exposure to arsenic may have detrimental health effects, particularly carcinogenesis.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Food Science & Technology
Robert A. Freeborn, Allison P. Boss, Luca M. Kaiser, Elizabeth M. Gardner, Cheryl E. Rockwell
Summary: This study found that arsenic has long-term effects on human T cell immune function, including reducing cell viability, altering cell activation, decreasing memory cell population, and reducing IFN gamma and granzyme B production. These findings contribute to a better understanding of the impact of arsenic on influenza immune response.
FOOD AND CHEMICAL TOXICOLOGY
(2022)
Article
Environmental Sciences
Mengliang Wu, Chunrong Pang, Shengwen Lu, Thomas H. Hostetter, Xin Hai
Summary: Our study investigated the impact of type 2 diabetes (T2DM) on arsenic metabolism in acute promye-locytic leukemia (APL) patients treated with arsenic trioxide. We discovered that APL patients with T2DM had significantly higher concentrations of arsenic metabolites compared to non-diabetic patients, and this increase was positively correlated with blood glucose levels. Additionally, APL patients with T2DM were more susceptible to liver injury and QTc interval prolongation due to altered arsenic methylation capacity. In in vitro experiments, we cultured HEK293T cells under different glucose concentrations and observed higher concentrations of arsenic metabolites in cells with high glucose. Moreover, high glucose levels significantly increased the expression of the arsenic uptake transporter AQP7 in HEK293T cells at the mRNA and protein levels. Overall, our study demonstrated that T2DM can lead to elevated concentrations of arsenic metabolites in APL patients by increasing AQP7 expression.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2023)
Article
Oncology
Xiao-Bo Wang, Li-Hua Yuan, Le-Ping Yan, Yong-Bin Ye, Bo Lu, Xiaojun Xu
Summary: This study reveals the significant role of UNC13B gene in arsenic trioxide resistance in chronic myeloid leukemia, and suggests that it may modulate apoptosis and proliferation through the mediation of MAP3K7, CDK4, and PINK1.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zhuo Zhang, Shunji Zhang, Fan Zhang, Qian Zhang, Hong Wei, Ruolin Xiu, Yanhong Zhao, Meijuan Sui
Summary: This study aimed to explore noninvasive clinical indicators that can guide the individualized use of arsenic trioxide (ATO) in the future. The results revealed that hemoglobin >= 80 g/L, nonprophylactic hepatoprotective agents, non-single-agent ATO, and decreased fibrinogen < 1 g/L were risk factors for ATO-induced hepatotoxicity in newly diagnosed APL patients.
BIOLOGICAL TRACE ELEMENT RESEARCH
(2023)
Article
Cell Biology
Junfen Xu, Yuanming Shen, Conghui Wang, Sangsang Tang, Shiyuan Hong, Weiguo Lu, Xing Xie, Xiaodong Cheng
Summary: Combination therapy of PARP inhibitors and arsenic compound shows significant therapeutic effects in HR-proficient ovarian cancer, including suppression of cell proliferation, induction of DNA damage, and promotion of apoptosis.
CELL DEATH DISCOVERY
(2021)
Article
Oncology
Jun-Zhu Chen, Li-Na Wang, Xue-Qun Luo, Yan-Lai Tang
Summary: This study constructed a genome-wide CRISPR-Cas9 knockdown screening system to identify relevant genes and pathways affecting the sensitivity of the anticancer drug arsenic trioxide (ATO). The results showed that KEAP1 is a critical gene regulating ATO drug sensitivity and may interact with certain clinical drugs. These findings provide new insights into the pharmacological mechanism of ATO and its potential applications in cancer treatments.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Li Chen, Hong-Ming Zhu, Yan Li, Qi-Fa Liu, Yu Hu, Jian-Feng Zhou, Jie Jin, Jian-Da Hu, Ting Liu, De-Pei Wu, Jie-Ping Chen, Yong-Rong Lai, Jian-Xiang Wang, Juan Li, Jian-Yong Li, Xin Du, Xin Wang, Ming-Zhen Yang, Jin-Song Yan, Gui-Fang Ouyang, Li Liu, Ming Hou, Xiao-Jun Huang, Xiao-Jing Yan, Dan Xu, Wei-Ming Li, Deng-Ju Li, Yin-Jun Lou, Zheng-Jun Wu, Ting Niu, Ying Wang, Xiao-Yang Li, Jian-Hua You, Hui-Jin Zhao, Yu Chen, Yang Shen, Qiu-Sheng Chen, Jian Li, Bing-Shun Wang, Wei-Li Zhao, Jian-Qing Mi, Kan-Kan Wang, Jiong Hu, Zhu Chen, Sai-Juan Chen, Jun-Min Li
Summary: This study found that the combination of all-trans retinoic acid and arsenic trioxide in treating acute promyelocytic leukemia during consolidation therapy is not inferior to traditional chemotherapy regimens and shows better outcomes in reducing relapse and toxicity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)